US court narrows rules for judging patent disputes:
This article was originally published in Clinica
In a ruling that impinges on the medical device industry, the US Federal Appeals Court has said that state adjudication in intellectual property matters cannot rely on common law standards such as fraud, but can only be judged by US patent law. The US Court of Appeals for the Federal Circuit reversed a $45 million decision against American Cyanamid last week which was based on claims of fraudulent non-disclosure and unjust enrichment alleged by two doctors from the University of Colorado.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.